Alzheimers Disease Therapeutics Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook 2026-2030

The global Alzheimer's disease therapeutics market encompasses approved pharmacological treatments for Alzheimer's disease, the most common form of dementia. Valued at approximately $5.15 billion in 2025, the market spans cholinesterase inhibitors, NMDA receptor antagonists, combination therapies, and emerging pipeline drugs. The market is experiencing a transformative period with the introduction of disease-modifying biologics targeting amyloid plaques, marking a shift from purely symptomatic treatments toward therapies that may slow disease progression.

• •Market valued at approximately $5.15 billion in 2025 with a 9.3% compound annual growth rate
• •Current treatments primarily include cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and NMDA receptor antagonists (memantine)
• •Recent FDA approvals of amyloid-targeting monoclonal antibodies (lecanemab, donanemab) are reshaping the treatment landscape

The aging global population is the primary demographic force propelling market expansion, as Alzheimer's disease risk increases significantly with age. Advances in early diagnosis through biomarker testing and imaging techniques are enabling intervention at earlier disease stages, expanding the addressable patient population. Growing awareness among healthcare providers and patients, combined with regulatory support for accelerated approval pathways, is further accelerating market growth.

• •Rising prevalence of Alzheimer's disease driven by the growing elderly population, with over 55 million people living with dementia worldwide
• •Increased diagnosis rates and earlier intervention enabled by improved biomarker testing, blood-based diagnostics, and amyloid PET imaging
• •Regulatory frameworks supporting accelerated approval for novel therapies, particularly disease-modifying treatments targeting amyloid-beta

The market is segmented by drug class into cholinesterase inhibitors, NMDA receptor antagonists, combination therapies, and pipeline drugs, with cholinesterase inhibitors historically dominating. Regionally, North America leads the market due to high disease prevalence, advanced healthcare infrastructure, and early adoption of new therapies like Leqembi. Europe and Asia-Pacific represent significant and growing markets, with the latter expected to expand rapidly due to increasing healthcare investment and aging populations.

• •Cholinesterase inhibitors constitute the largest segment by revenue, with combination therapies gaining prominence
• •North America accounts for the largest regional share, supported by FDA approvals and higher treatment uptake
• •Asia-Pacific is the fastest-growing region, driven by improving healthcare access and rising elderly populations in countries like China and Japan

What are the recent trends and outlook?

The market is shifting toward disease-modifying therapies that target underlying pathophysiology rather than merely managing symptoms, with biologics representing the fastest-growing segment. Integration of digital health tools, artificial intelligence for drug discovery, and personalized medicine approaches based on biomarker profiles are expected to further accelerate innovation. Over the forecast period, the combination of new approvals, expanding reimbursement coverage, and continued pipeline development is projected to sustain the 9.3% CAGR through 2030.

• •Disease-modifying biologics targeting amyloid-beta and tau proteins are expected to capture an increasing share of a market projected to exceed $10 billion by 2030
• •Blood-based biomarker tests and digital cognitive assessments are enabling earlier and more accessible diagnosis, expanding treatment eligibility
• •Combination therapies and next-generation antibodies with improved safety profiles are under active development to address current treatment limitations